Last reviewed · How we verify
NCT05224622
Detection of COVID-19 Using Breath Analysis - Validation Study.
NA trial testing VOX in COVID-19 in 192 participants. Completed in 18 January 2023.
28 May 2022
Quick facts
| Lead sponsor | Scentech Medical Technologies Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 192 |
| Start date | 18 January 2022 |
| Primary completion | 28 May 2022 |
| Estimated completion | 18 January 2023 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- VOX — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Scentech Medical Technologies Ltd
Who can join
Adults 18 to 75, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Detection of the 2019 novel Coronavirus (SARS-CoV-2) using breath analysis - Validation study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05224622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VOX
Trials testing the same drug.
- NCT05400408 — Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study · NA · unknown
- NCT05399615 — Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study · NA · withdrawn
- NCT02533427 — Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Represent · Phase 1 · completed
- NCT02378935 — Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 · Phase 2 · completed
- NCT02378961 — Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genoty · Phase 2 · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Scentech Medical Technologies Ltd trials
Trials by the same sponsor.
- NCT05400408 — Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study · NA · unknown
- NCT05399615 — Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study · NA · withdrawn
- NCT04842708 — Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis · NA · completed
- NCT04602949 — Detection of COVID-19 Using Breath Analysis - Validation Study · NA · completed
- NCT04602884 — Early Detection of COVID-19 Using Breath Analysis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05224622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Scentech Medical Technologies Ltd
- Last refreshed: 31 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05224622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing